Buradasınız

Tip 1 Glikojen Depo Hastalığı Olan Bir Çocukta Distal Renal Tübüler Disfonksiyon ve Kalsiyum Taş Hastalığı: Vaka Sunumu

Journal Name:

Publication Year:

Abstract (2. Language): 
Type 1 glycogen storage disease is caused by glucose-6-phospha-tase deficiency and nephrolithiasis is the most common renal compli¬cation. Although urate stones are the most common stone type, meta¬bolic alterations favoring calcium nephrolithiasis has also been desc¬ribed in these patients. We report a pediatric case with type 1 glycogen storage disease presenting with recurrent macroscopic hematuria that was diagnosed to have calcium stone disease. The patient had multiple metabolic abnormalities including hypercalciuria, hyperoxa-luria, hypocitraturia and hypomagnesuria.
Abstract (Original Language): 
Tip 1 glikojen depo hastalığı glukoz-6-fosfataz eksikliği sonucu oluşur ve nefrolitiyazis en sık renal komplikasyonudur. Ürat taşları en sık görülen taş tipi olsa da, bu vakalarda meydana gelen metabolik değişiklikler sonucu kalsiyum taşları da bildirilmektedir. Bu yazıda tip 1 glikojen depo hastalığı tanısı ile izlenen, tekrarlayan makroskopik he-matüri nedeni ile kliniğimize başvuran ve kalsiyum taş hastalığı saptanan bir vaka sunulmaktadır. Vakada aynı zamanda hiperkalsiüri, hipe-roksalüri, hipositratüri ve hipomagnezüriyi içeren birçok metabolik anormallik de saptanmıştır.
FULL TEXT (PDF): 
182-185

REFERENCES

References: 

1. Chen YT. Defects in metabolism of carbohydrates. In: Behr-man RE, Kliegman RM, Jenson HB (eds), Nelson Textbook
Tip 1
Glikojen Depo Hastalığı Olan Bir Çocukta Distal Renal Tübüler Disfonksiyon ve Kalsiyum Taş Hastalığı: Vaka Sunumu
of Pediatrics, 16th Ed. W.B. Saunders Company, Philadelphia, 2000, p:405-420.
2.
Simöe
s A, Domingos F, Fortes A, Prata MM. Type 1 glyco-gen storage disease and recurrent calcium urolithiasis. Nephrol Dial Transplant 2001;16:1277-1279.
3. Levy E, Thibault L, Turgeon J, Roy CC, Gurbindo C, Lepage G, et al. Beneficial effects of fish-oil supplements on lipids, lipoproteins, and lipoprotein lipase in patients with glyco-gen storage disease type I. Am J Clin Nutr 1993;57:922-929.
4. Scheinman JI. Glycogen storage disease. In: Barrat TM, Av-ner ED, Harmon WE (eds), Pediatric Nephrology, 4th Ed. Lippincott Williams and Wilkins, Baltimore, 1999, p: 621¬624.
5. Chen YT, Coleman RA, Scheinman JI, Kolbeck PC, Sidbury JB. Renal disease in type 1 glycogen storage disease. N Engl
J Med 1988; 318:7-11.
6. Restaino I , Kaplan BS, Stanley C , Baker L. Nephrolithiasis, hypocitraturia, and a distal tubular acidification defect in type 1 glycogen storage disease. J Pediatr 1993; 122:392-6.
7. Lee PJ, Dalton RN, Shah V, Hindmarsh PC, Leonard JV. Glo-
merular and tubular function in glycogen storage disease.
Pediatr Nephrol 1995; 9:705-10.
8. Iida S, Matsuoka K, Inoue M, Tomiyasu K, Noda S. Calcium nephrolithiasis and distal tubular acidosis in type 1 glycogen storage disease. Int J Urol 2003; 10:56-58.
9. del Valle E, Spivacow R, Zanchetta JR. Metabolic changes in 2612 patients with nephrolithiasis (abstract). Medicina (B Aires) 1999; 59:417-422.
10. Greenberg A. Diuretic complications. Am J Med Sci 2000; 319:10-24.
Official

Thank you for copying data from http://www.arastirmax.com